<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19281083</article-id><article-id pub-id-type="pmc">2650596</article-id><article-id pub-id-type="publisher-id">copd-3-693</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Richter</surname><given-names>Daphne C</given-names></name><xref ref-type="aff" rid="af1-copd-3-693">1</xref></contrib><contrib contrib-type="author"><name><surname>Joubert</surname><given-names>James R</given-names></name><xref ref-type="aff" rid="af1-copd-3-693">1</xref></contrib><contrib contrib-type="author"><name><surname>Nell</surname><given-names>Haylene</given-names></name><xref ref-type="aff" rid="af1-copd-3-693">1</xref></contrib><contrib contrib-type="author"><name><surname>Schuurmans</surname><given-names>Mace M</given-names></name><xref ref-type="aff" rid="af2-copd-3-693">2</xref></contrib><contrib contrib-type="author"><name><surname>Irusen</surname><given-names>Elvis M</given-names></name><xref ref-type="aff" rid="af2-copd-3-693">2</xref><xref ref-type="corresp" rid="c1-copd-3-693"/></contrib></contrib-group><aff id="af1-copd-3-693"><label>1</label> Tiervlei Trial Centre, Karl Bremer Hospital, Bellville, RSA</aff><aff id="af2-copd-3-693"><label>2</label> Respiratory Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of Stellenbosch, RSA</aff><author-notes><corresp id="c1-copd-3-693">Correspondence: EM Irusen, Respiratory Research Unit, Department of Internal Medicine, Faculty of Health Sciences, PO Box 19063, Tygerberg 7505, RSA, Tel +27 219389423, Fax +27 219333591, Email<email>eirusen@sun.ac.za</email></corresp></author-notes><!--Dove Press titles changed from ppub to collections in 2009.								Fake epub written to satisfy Base Date Type=epub--><pub-date pub-type="ppub"><month>12</month><year>2008</year></pub-date><pub-date pub-type="epub"><month>12</month><year>2008</year></pub-date><volume>3</volume><issue>4</issue><fpage>693</fpage><lpage>699</lpage><copyright-statement>&#x000a9; 2008 Dove Medical Press Limited. All rights reserved</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Objective</title><p>The GOLD guidelines suggest that the presence of a post-bronchodilator forced expiratory volume in one second (FEV<sub>1</sub>) &#x0003c; 80% of the predicted value in combination with a FEV<sub>1</sub>/forced vital capacity (FVC) &#x0003c; 70% confirms the diagnosis of COPD. Limited data exist regarding the accuracy of these criteria to distinguish between COPD and asthma. The aim of this study therefore was to investigate the diagnostic value of post-bronchodilator lung function parameters in obstructive lung disease.</p></sec><sec sec-type="methods"><title>Methods</title><p>The pulmonary function tests of 43 (22 = COPD, 21 = asthma) patients with similar baseline characteristics were evaluated (baseline FEV<sub>1</sub> were 55.7% &#x000b1; 7.6%, and 59.3% &#x000b1; 8.4% predicted for COPD and asthma, respectively). Bronchodilator responsiveness (BDR) was calculated according to three recognized pulmonary function test criteria.</p></sec><sec><title>Results</title><p>The first criteria, post-bronchodilator FEV<sub>1</sub> &#x0003c; 80% of the predicted value in combination with a post-bronchodilator FEV<sub>1</sub>/FVC ratio of &#x0003c;70%, had an accuracy of 70% to diagnose COPD. This combination was very sensitive (100%) in diagnosing COPD, but it was not specific (38%). The second BDR criteria, defined as an increase of &#x0003c;12% and 200 mL of initial FEV<sub>1</sub> and criterion number 3, an increase of &#x0003c; 9% of predicted FEV<sub>1</sub>, were less sensitive (55% and 59%, respectively), but more specific (81% and 76% respectively) to diagnose COPD. Our findings suggest that the current recommended spirometric indices are not optimal in differentiating between COPD and asthma.</p></sec></abstract><kwd-group><kwd>obstructive lung disease</kwd><kwd>diagnosis</kwd><kwd>post-bronchodilator pulmonary function test</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>COPD and asthma are common conditions and their worldwide prevalence is expected to increase over the next twenty years (<xref ref-type="bibr" rid="b19-copd-3-693">Murray and Lopez 1997</xref>). Although the two diseases share many clinical features, there are important clinical and pathological differences influencing choice of medication and long-term aims of management (<xref ref-type="bibr" rid="b15-copd-3-693">Jeffrey 1998</xref>; <xref ref-type="bibr" rid="b8-copd-3-693">Celli 2000</xref>; <xref ref-type="bibr" rid="b14-copd-3-693">Fabri et al 2003</xref>).</p><p>The degree of reversibility following bronchodilator administration has played a pivotal role in the evaluation of obstructive lung disease, thereby influencing drug choice and patterns of care (<xref ref-type="bibr" rid="b12-copd-3-693">Dow 1999</xref>). In addition to the clinical importance, bronchodilator testing can have regulatory importance as European regulators now require that COPD patients included in clinical trials meet the ERS definition of irreversible disease (<xref ref-type="bibr" rid="b5-copd-3-693">Calverley et al 2003</xref>). Significant reversibility is denoted by the American Thoracic Society (ATS) as a change of &#x0003e;12% of the baseline forced expiratory volume in one second (FEV<sub>1</sub>) if this also exceeds 200 mL, while the European Respiratory Society (ERS) recommends a change of &#x0003e;9% of the predicted FEV<sub>1</sub> (<xref ref-type="bibr" rid="b1-copd-3-693">American Thoracic Society 1991</xref>; <xref ref-type="bibr" rid="b24-copd-3-693">Quanjer et al 1993</xref>). The numerous ways of expressing BDR have been challenged repeatedly (<xref ref-type="bibr" rid="b30-copd-3-693">Weir and Burge 1991</xref>; <xref ref-type="bibr" rid="b3-copd-3-693">Brand et al 1992</xref>; <xref ref-type="bibr" rid="b11-copd-3-693">Dompeling et al 1992</xref>). Although historically used to diagnose asthma, none of these current definitions are sensitive or sufficiently specific to differentiate asthma from COPD purely on spirometric grounds (<xref ref-type="bibr" rid="b18-copd-3-693">Meslier et al 1989</xref>;Bran et al 1992; <xref ref-type="bibr" rid="b26-copd-3-693">Quedrelli et al 1999b</xref>).</p><p>The GOLD guidelines suggest that the diagnosis of COPD should be confirmed by spirometry. The presence of a post-bronchodilator FEV<sub>1</sub> &#x0003c; 80% of the predicted value in combination with a FEV<sub>1</sub>/FVC &#x0003c; 70% confirms the presence of airflow limitation that is not fully reversible (<xref ref-type="bibr" rid="b22-copd-3-693">Pauwels et al 2001</xref>). The usefulness of these post-bronchodilator spirometric variables as diagnostic criteria in BDR testing has to our knowledge not been assessed systematically in patients with obstructive lung disease.</p><p>The aim of our study, therefore, was to investigate the accuracy of a number of spirometric criteria used to express the BDR and assess how well they are able to distinguish between COPD and asthma in our study population. We hypothesized that the post-bronchodilator FEV<sub>1</sub> &#x0003c;80% of the predicted in combination with a FEV<sub>1</sub>/FVC ratio of &#x0003c; 70% would be more sensitive and specific to distinguish COPD from asthma than the use of ATS and ERS BDR criteria in moderately severe obstructive lung disease.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>Consecutive subjects with airways obstruction, meeting inclusion criteria as specified below, were prospectively recruited. All participants had to be able to perform technically acceptable pulmonary function tests. Medical histories, including specific respiratory symptoms, were obtained in a standardized manner. Inclusion criteria for the COPD group were a smoking history of more than ten pack years, associated with chronic cough and/or sputum production with an onset of symptoms after 40 years of age. An exclusion criterion for the COPD group was a history of asthma. The asthma group had to be older than 40 years of age with recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. In addition, these subjects had to be ex- or nonsmokers with a less than ten pack year history. All patients had to be clinically stable with no respiratory exacerbations for six weeks prior to inclusion in the study and no changes in chronic medication during this period. Respiratory exacerbations were defined as an increase in breathlessness, sputum volume or sputum purulence from baseline requiring treatment with prednisone and/or antibiotics.</p><p>To ensure comparable baseline characteristics, we included only patients with a pre-bronchodilator FEV<sub>1</sub>% predicted of between 40% and 70% as well as a FEV<sub>1</sub>/FVC ratio between 45% and 65%, as the population of moderately severe obstructive lung disease poses the greatest challenge in differentiating COPD from asthma.</p></sec><sec><title>Study design</title><p>All subjects signed written informed consent for participation in the study. The local ethics committee approved the study. Bronchodilator treatment was withdrawn prior to pulmonary function testing according to standard practice (immediate release theophylline: 24 hours, long acting &#x003b2;<sub>2</sub>-agonist: 12 hours, short acting &#x003b2;<sub>2</sub>-agonist: 6 hours and short acting anticholinergic: 8 hours).</p></sec><sec><title>Procedures</title><p>A qualified pulmonary technologist conducted maximal in-and expiratory flow volume curves with subjects seated before (&#x02018;pre&#x02019;) and after (&#x02018;post&#x02019;) administration of 400 &#x003bc;g salbutamol. The medication was given via a metered dose inhaler with a large volume spacer (Volumatic, GlaxoSmithKline). ATS guidelines (1994) were adhered to concerning spirometric assessments, calibration and equipment maintenance. All pulmonary function measurements were made using a Jaeger Masterscope 4.0 spirometer (W&#x000fc;rzburg, Germany). Predicted normal values were calculated as laid down by the European Community for Coal and Steel (ECCS). For analysis, the best FEV<sub>1</sub> and forced vital capacity (FVC) were chosen regardless of the curve. The &#x02018;best test&#x02019; curve was selected from the largest sum of FEV<sub>1</sub> and FVC. All other lung function parameters selected for analysis were taken from the &#x02018;best test&#x02019; curve.</p></sec><sec><title>Evaluation of bronchodilator response</title><p>Bronchodilator responsiveness (BDR) was calculated according to the following three criteria: 1) FEV<sub>1</sub> post-bronchodilator &#x0003c; 80% predicted and FEV<sub>1</sub>/FVC ratio &#x0003c; 70%, 2) FEV<sub>1</sub> change from initial (FEV<sub>1</sub> %&#x00394;init: post FEV<sub>1</sub> &#x02013; pre FEV<sub>1</sub>/pre FEV<sub>1</sub> &#x000d7; 100) less than 12% and FEV<sub>1</sub> absolute change (FEV<sub>1</sub> abs &#x00394;: post FEV <sub>1</sub> &#x02013; pre FEV<sub>1</sub>) less than 200 mL (according to ATS guidelines) (<xref ref-type="bibr" rid="b1-copd-3-693">American Thoracic Society 1991</xref>) and 3) FEV<sub>1</sub> change from predicted (FEV<sub>1</sub> %&#x00394;pred: post FEV<sub>1</sub> &#x02013;pre FEV<sub>1</sub>/predicted FEV<sub>1</sub> &#x000d7; 100) less than 9% (according to ERS guidelines) (<xref ref-type="bibr" rid="b24-copd-3-693">Quanjer et al 1993</xref>).</p></sec><sec><title>Data analysis</title><p>Results are presented as means &#x000b1; standard error of mean. A p value of &#x0003c; 0.05 was considered significant. Descriptive group data were compared using the unpaired student t-test. Differences among the groups were evaluated using analysis of variance (ANOVA). The sensitivity and specificity as well as the predictive values and accuracy of a BDR to salbutamol in distinguishing patients with COPD and asthma were calculated for the three criteria as outlined above.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Subject characteristics</title><p>104 patients with COPD and 127 patients with asthma were evaluated consecutively. 22 COPD and 21 asthma patients with a baseline FEV<sub>1</sub> of 55.7% &#x000b1; 7.6%, and 59.3% &#x000b1; 8.4% predicted respectively met the inclusion criteria and were included for further analyses.</p><p>Subject characteristics are outlined in <xref ref-type="table" rid="t1-copd-3-693">Table 1</xref>. The COPD and asthma groups had comparable baseline pre-bronchodilator pulmonary function tests and demographics.</p><p>All subjects were on short acting &#x003b2;<sub>2</sub>-agonist therapy. 9 (41%) COPD patients were on inhaled or oral corticosteroids, 5 (23%) were on long acting &#x003b2;<sub>2</sub>-agonist therapy and 8 (36%) were on theophylline. All asthmatic patients were on inhaled steroids. No asthmatic patient was on oral steroids, theophylline or long acting &#x003b2;<sub>2</sub>-agonist therapy. Subgroup analysis showed that corticosteroid treatment did not significantly influence bronchodilator response within the COPD group (p &#x0003c; 0.07, data not shown).</p></sec><sec><title>Bronchodilator responses</title><p>Spirometric changes in response to salbutamol are shown in <xref ref-type="table" rid="t2-copd-3-693">Table 2</xref>. After salbutamol inhalation there was a statistically significant increase of all flow volume curve parameters in both groups. The mean responses were significantly greater for the asthma group for all the FEV<sub>1</sub> criteria (<xref ref-type="table" rid="t2-copd-3-693">Table 2</xref>). The absolute change in FVC after bronchodilator administration was significantly greater in the asthma subjects in comparison to the COPD group (<xref ref-type="table" rid="t2-copd-3-693">Table 2</xref>). The FEF<sub>50</sub> showed a significant response to salbutamol in the asthma patients, but not in the subjects with COPD (<xref ref-type="table" rid="t2-copd-3-693">Table 2</xref>). The pre- and post-bronchodilator FEV<sub>1</sub>/FVC ratio remained almost the same in the COPD group, whereas in comparison the ratio increased significantly (p = 0.003) in the asthma group (<xref ref-type="fig" rid="f1-copd-3-693">Figure 1</xref>). The post bronchodilator FEV<sub>1</sub> % predicted was significantly (p = 0.0002) lower in the COPD group (<xref ref-type="fig" rid="f1-copd-3-693">Figure 1</xref>). All COPD and 13 (62%) of asthma patients fulfilled the first tested BDR criteria (FEV<sub>1</sub> post-bronchodilator &#x0003c; 80% predicted and FEV<sub>1</sub>/FVC ratio &#x0003c;70%). 12 (55%) COPD and 4 (19%) Asthma patients had a positive response according to the second criteria of a BDR &#x0003c; 12% and FEV<sub>1</sub> absolute change &#x0003c;200 mL. The third BDR criteria, FEV<sub>1</sub> change from predicted &#x0003c;9%, was fulfilled in 13 (59%) COPD and 5 (24%) asthma patients. There was a significant difference between the two groups in the FEV<sub>1</sub> bronchodilator response when expressed as a percentage of the initial value (p = 0.001) as well as for the change from predicted criteria ( p = 0.0003) (<xref ref-type="fig" rid="f2-copd-3-693">Figure 2</xref>).</p><p>The sensitivity, specificity, predictive values and accuracy of diagnosing COPD for each of the three BDR criteria, as defined above, are given in <xref ref-type="table" rid="t3-copd-3-693">Table 3</xref>. Although the first criteria tested (FEV<sub>1</sub> post-bronchodilator &#x0003c;80% predicted and FEV<sub>1</sub>/FVC ratio &#x0003c;70%) proved to be the most sensitive (100%) to diagnose COPD, it was the least specific (38%) criteria to rule out asthma. The second (BDR &#x0003c; 12% <italic>and</italic> FEV<sub>1</sub> absolute change &#x0003c;200 mL) and third (FEV1 change from predicted &#x0003c;9%) criteria had a specificity of 81% and 76% respectively with a sensitivity of 55% and 59% respectively</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Although previous studies have examined the ability of different BDR indices to distinguish between COPD and asthma, the diagnostic value of the post-bronchodilator FEV<sub>1</sub>/FVC ratio and FEV<sub>1</sub> &#x0003e; 80% predicted have to our knowledge not been assessed systematically in a group of obstructive lung disease patients with comparable baseline lung function severity. Our data suggest that the post-bronchodilator FEV<sub>1</sub> &#x0003e; 80% predicted in combination with a post-bronchodilator FEV<sub>1</sub>/FVC ratio &#x0003e;70% are more sensitive in diagnosing COPD, but it is less specific than the current ATS and ERS BDR indices (BDR &#x0003c; 12% <italic>and</italic> FEV<sub>1</sub> absolute change &#x0003c;200 mL or FEV1 change from predicted &#x0003c;9%) (<xref ref-type="bibr" rid="b1-copd-3-693">American Thoracic Society 1991</xref>; <xref ref-type="bibr" rid="b24-copd-3-693">Quanjer et al 1993</xref>).</p><p>The usefulness of classifying patients based on their response to bronchodilator administration has significant limitations (<xref ref-type="bibr" rid="b5-copd-3-693">Calvery et al 2003</xref>). The evaluation of therapeutic efficacy needs to be reassessed and the traditional reliance on an improved post-bronchodilator FEV<sub>1</sub> has clear limitations (Pellegrino et al 1993; <xref ref-type="bibr" rid="b21-copd-3-693">O&#x02019;Donnell 2000</xref>). The use of exercise testing with reliable subjective measurements of dyspnea and quality of life has been found to be more sensitive to adequately predict a positive clinical response to bronchodilator therapy, but this comprehensive therapeutic assessment of bronchodilator efficacy may not be feasible for many clinicians managing COPD (<xref ref-type="bibr" rid="b21-copd-3-693">O&#x02019;Donnell 2000</xref>). An additional advantage of the FEV<sub>1</sub>/FVC fixed ratio could be that only one post-bronchodilator flow volume curve is required, and the need for calculation of a BDR is eliminated, which means that this approach would be timesaving and less susceptible to calculation errors.</p><p>It is known that the BDR is significantly influenced by the degree of baseline impairment when expressed as a percentage of the initial flow volume curve value (<xref ref-type="bibr" rid="b13-copd-3-693">Eliasson and Degraff 1985</xref>; <xref ref-type="bibr" rid="b5-copd-3-693">Calverley et al 2003</xref>). Despite the fact that patients with more severe obstruction will show a greater improvement than patients with a higher baseline value, this criteria is still used at times as part of the inclusion or exclusion criteria for pharmaceutical trials, and it can lead to inaccurate clinical diagnoses affecting patient management. Due to this well known fact we chose to include only patients with comparable baseline lung function impairment. This inclusion criterion resulted in relatively low numbers of patients ultimately included in the final analysis and this could be a possible limitation of our study.</p><p>Instead of looking at degrees of reversibility that exceed arbitrary thresholds, a more useful feature for confirmation of COPD is that the patient&#x02019;s lung function does not return to normal after bronchodilator administration (Calverley and Walker). Unfortunately when applying the GOLD criteria in our group of obstructive lung disease patients 62% of the asthma patients fulfilled the diagnosis for COPD purely on spirometric grounds. It is a well known fact that a percentage of patients with chronic severe asthma have persistent airflow obstruction (Bumbacea et al 2003).</p><p>In our study population, there was a significantly greater improvement in FEF<sub>50</sub> in the asthma group compared to the COPD group (<xref ref-type="table" rid="t2-copd-3-693">Table 2</xref>). This sensitive parameter may be useful for long term studies in individuals when onset of disease is sought (<xref ref-type="bibr" rid="b10-copd-3-693">Cochrane et al 1977</xref>). It is, however, not recommended for routine assessment of the BDR due to intra-individual variability (<xref ref-type="bibr" rid="b16-copd-3-693">Knudson et al 1983</xref>).</p><p>Despite the inherent interdependence of FEV<sub>1</sub> and FVC, we found a differential response of the FEV<sub>1</sub>/FVC ratio between the two groups (<xref ref-type="fig" rid="f1-copd-3-693">Figure 1</xref>). Due to a greater FEV<sub>1</sub> compared to FVC response in the asthma group (<xref ref-type="table" rid="t2-copd-3-693">Table 2</xref>), the FEV<sub>1</sub>/FVC ratio significantly (<italic>p</italic> = 0.003) increased in the asthma group, but remained low in the COPD group after bronchodilatation. On close examination of previously published results it is interesting to note that the FVC response appears to be generally greater than the FEV<sub>1</sub> response in COPD patients, but the inclusion criteria for these studies varied considerably, and no mention is made of the significance of the differences observed (<xref ref-type="bibr" rid="b5-copd-3-693">Calverley et al 2003</xref>; <xref ref-type="bibr" rid="b20-copd-3-693">Newton et al 2002</xref>). The choice of lung function tests for a given purpose should take into consideration the degree of variability of that test if the interpretation is not to be misleading (<xref ref-type="bibr" rid="b17-copd-3-693">McCarthy et al 1975</xref>). <xref ref-type="bibr" rid="b28-copd-3-693">Tweeddale and colleagues (1987)</xref> found that the increase in FEV<sub>1</sub> and FVC that excluded natural variability with 95% confidence in patients with obstructive ventilatory defects was 160 mL and 330 mL respectively. Whether these values are applicable for both COPD and asthma was not specified in that study. Despite this inherent difference between these two lung function parameters, the ATS guidelines suggest an increase after bronchodilator administration of more than 200 mL in either FEV<sub>1</sub> or FVC to be significant which may lead to diagnostic misclassification (<xref ref-type="bibr" rid="b1-copd-3-693">American Thoracic Society 1991</xref>).</p><p>The post-bronchodilator FEV<sub>1</sub> &#x0003e; 80% predicted parameter has the disadvantage of requiring a set of predicted values applicable to a specific population group, making comparison of international studies difficult. Using a fixed percentage of the predicted value as the lower limit of normal can therefore result in inappropriate classification of patients (<xref ref-type="bibr" rid="b25-copd-3-693">Quedrelli et al 1999a</xref>).</p><p>Using a fixed FEV<sub>1</sub>/FVC ratio as the lower limit of normal has recognized limitations (<xref ref-type="bibr" rid="b16-copd-3-693">Knudson et al 1983</xref>; <xref ref-type="bibr" rid="b1-copd-3-693">American Thoracic Society 1991</xref>). It has, however, been suggested by some authors to offer certain benefits as a compromise solution among competing definitions of obstruction, in that the fixed ratio is easy to remember and does not require the use of population specific reference tables (<xref ref-type="bibr" rid="b7-copd-3-693">Celli et al 2003</xref>). This assumption remains to be verified in large population based studies. It cannot be emphasized enough that no single spirometric parameter or index will take the place of clinical evaluation in diagnosing patients with COPD or asthma, but spirometry is supplementary and remains the objective cornerstone (<xref ref-type="bibr" rid="b22-copd-3-693">Pauwels et al 2001</xref>). Agreement should be reached internationally on the spirometric evaluation of patients with obstructive lung disease. Different criteria used to define obstruction and reversibility will result in vastly different prevalence rates of obstructive lung diseases in the general population and it complicates international comparisons of studies (<xref ref-type="bibr" rid="b29-copd-3-693">Viegi et al 2000</xref>; <xref ref-type="bibr" rid="b7-copd-3-693">Celli et al 2003</xref>). It is time that the appropriateness of definitions used to date is reconsidered.</p><p>The lung function data for each patient on our study can be seen as a snap shot and longitudinal reevaluation would have been ideal. Fluctuation in airway function is a well known fact, and it has to be taken into account in the evaluation of patients that the lungs are a complex and dynamic system. Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD (<xref ref-type="bibr" rid="b9-copd-3-693">Chhabra 2005</xref>). It does not help that the guidelines focuses on post bronchodilator FEV<sub>1</sub> for COPD and pre bronchodilator values for asthma when it comes to classification of disease severity (<xref ref-type="bibr" rid="b27-copd-3-693">Sterk 2004</xref>).</p><p>In an attempt to keep the groups clinically diagnosed with COPD or asthma as &#x0201c;pure&#x0201d; as possible, we did not include asthmatic smokers, patients with known combined disease or patients with COPD in the absence of a strong smoking history. The selection criteria of COPD and asthma patients could therefore potentially be seen as artificial. All of these groups would warrant special attention in clinical practice, but for the purposes of the article it was impossible to include them.</p><p>In our study population the post-bronchodilator FEV<sub>1</sub> &#x0003c; 80% predicted in combination with the FEV<sub>1</sub>/FVC ratio value &#x0003e;70% (criteria #1) was very sensitive (100%) in diagnosing COPD. Unfortunately the criteria were unable to distinguish reliably between patients with COPD and asthma as 62% of asthmatic patients did not achieve &#x0201c;normal&#x0201d; spirometry in the stage of obstructive lung disease studied here. The conventional BDR criteria (criteria #2 FEV<sub>1</sub> &#x0003c; 12% and absolute change &#x0003c;200 mL, criteria #3 FEV<sub>1</sub> change from predicted &#x0003c;9%) were specific, because a smaller percentage of asthma patients fell below the historically selected positive BDR response criteria, but it was less sensitive due to the positive BDR response in the COPD patients as well. It might be a good idea to combine the GOLD criteria (criteria #1) as well as the conventional BDR criteria (criteria #2) to increase the accuracy. In summary, asthmatic subjects show more reversibility than COPD subjects even when they have post-BD airflow obstruction. Adding the bronchodilator test in the diagnoses of COPD (GOLD) guidelines could help to reduce the misclassification of asthmatics with COPD.</p><p>In the evaluation of obstructive lung disease spirometry remains an investigative tool to confirm a clinical suspicion. Additional meaningful outcome measures are urgently needed to accurately distinguish between COPD and asthma.</p></sec></body><back><fn-group><fn><p><bold>Conflict of interest</bold></p><p>The authors report no conflict of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-copd-3-693"><citation citation-type="journal"><collab>American Thoracic Society</collab><year>1991</year><article-title>Lung function testing: selection of reference values and interpretative strategies</article-title><source>Am Rev Respir Dis</source><volume>144</volume><fpage>1202</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">1952453</pub-id></citation></ref><ref id="b2-copd-3-693"><citation citation-type="journal"><collab>American Thoracic Society</collab><year>1994</year><article-title>Standardization of spirometry: 1994 update</article-title><source>Am J Respir Crit Care Med</source><volume>152</volume><fpage>1107</fpage><lpage>36</lpage></citation></ref><ref id="b3-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>PLP</given-names></name><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><etal/></person-group><year>1992</year><article-title>Interpretation of bronchodilator response in patients with obstructive airways disease</article-title><source>Thorax</source><volume>47</volume><fpage>429</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">1496502</pub-id></citation></ref><ref id="b4-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bumbacea</surname><given-names>D</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><etal/></person-group><year>2004</year><article-title>Parameters associated with persistent airflow obstruction in chronic severe asthma</article-title><source>Eur Respir J</source><volume>24</volume><fpage>122</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15293614</pub-id></citation></ref><ref id="b5-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PMA</given-names></name><name><surname>Burge</surname><given-names>PS</given-names></name><name><surname>Spencer</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>Bronchodilator reversibility testing in chronic obstructive pulmonary disease</article-title><source>Thorax</source><volume>58</volume><fpage>659</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">12885978</pub-id></citation></ref><ref id="b6-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PMA</given-names></name><name><surname>Walker</surname><given-names>P</given-names></name></person-group><year>2003</year><article-title>Chronic obstructive pulmonary disease</article-title><source>Lancet</source><volume>362</volume><fpage>1053</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">14522537</pub-id></citation></ref><ref id="b7-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>BR</given-names></name><name><surname>Halbert</surname><given-names>RJ</given-names></name><name><surname>Isonaka</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>Population impact of different definitions of airway obstruction</article-title><source>Eur Respir J</source><volume>22</volume><fpage>268</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">12952259</pub-id></citation></ref><ref id="b8-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>BR</given-names></name></person-group><year>2000</year><article-title>The importance of spirometry in COPD and asthma. Effect on approach to management</article-title><source>Chest</source><volume>117</volume><fpage>15</fpage><lpage>9</lpage></citation></ref><ref id="b9-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chhabra</surname><given-names>SK</given-names></name></person-group><year>2005</year><article-title>Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD</article-title><source>J Asthma</source><volume>42</volume><fpage>367</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16036411</pub-id></citation></ref><ref id="b10-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cochrane</surname><given-names>GM</given-names></name><name><surname>Prieto</surname><given-names>F</given-names></name><name><surname>Clark</surname><given-names>TJH</given-names></name></person-group><year>1977</year><article-title>Intrasubject variability of maximal expiratory flow volume curve</article-title><source>Thorax</source><volume>32</volume><fpage>171</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">867329</pub-id></citation></ref><ref id="b11-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dompeling</surname><given-names>E</given-names></name><name><surname>van Schayck</surname><given-names>CP</given-names></name><name><surname>Molema</surname><given-names>J</given-names></name><etal/></person-group><year>1992</year><article-title>A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV<sub>1</sub></article-title><source>Eur Respir J</source><volume>5</volume><fpage>975</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">1426206</pub-id></citation></ref><ref id="b12-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dow</surname><given-names>L</given-names></name></person-group><year>1999</year><article-title>Asthma versus chronic obstructive pulmonary disease &#x02013; exploring why &#x0201c;reversibility versus irreversibility&#x0201d; is no longer an appropriate approach</article-title><source>Clin Exp Allergy</source><volume>29</volume><fpage>739</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">10336587</pub-id></citation></ref><ref id="b13-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eliasson</surname><given-names>O</given-names></name><name><surname>Degraff</surname><given-names>AC</given-names></name></person-group><year>1985</year><article-title>The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric and anthropometric variables</article-title><source>Am Rev Respir Dis</source><volume>132</volume><fpage>858</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">4051321</pub-id></citation></ref><ref id="b14-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Romagnoli</surname><given-names>M</given-names></name><name><surname>Corbetta</surname><given-names>L</given-names></name><etal/></person-group><year>2003</year><article-title>Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><volume>167</volume><fpage>418</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12426229</pub-id></citation></ref><ref id="b15-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeffrey</surname><given-names>PK</given-names></name></person-group><year>1998</year><article-title>Structural and inflammatory changes in COPD: a comparison with asthma</article-title><source>Thorax</source><volume>53</volume><fpage>129</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">9624299</pub-id></citation></ref><ref id="b16-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knudson</surname><given-names>RJ</given-names></name><name><surname>Lebowitz</surname><given-names>MD</given-names></name><name><surname>Holberg</surname><given-names>CJ</given-names></name></person-group><year>1983</year><article-title>Changes in the normal expiratory flow-volume curve with growth and aging</article-title><source>Am Rev Respir Dis</source><volume>127</volume><fpage>725</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">6859656</pub-id></citation></ref><ref id="b17-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>DS</given-names></name><name><surname>Craig</surname><given-names>DB</given-names></name><name><surname>Cherniack</surname><given-names>RM</given-names></name></person-group><year>1975</year><article-title>Intraindividual variability in maximal expiraoty flow-volume and closing volume in asymptomatic subjects</article-title><source>Am Rev Respir Dis</source><volume>112</volume><fpage>407</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">1163894</pub-id></citation></ref><ref id="b18-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meslier</surname><given-names>N</given-names></name><name><surname>Racineux</surname><given-names>JL</given-names></name><name><surname>Six</surname><given-names>P</given-names></name><etal/></person-group><year>1989</year><article-title>Diagnostic value of chronic obstruction to separate asthma from chronic bronchitis: a statistical approach</article-title><source>Eur Respir J</source><volume>2</volume><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">2744134</pub-id></citation></ref><ref id="b19-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJL</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name></person-group><year>1997</year><article-title>Alternative projections of mortality and disability by cause 1990&#x02013;2020. Global Burden of Disease Study</article-title><source>Lancet</source><volume>349</volume><fpage>1498</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">9167458</pub-id></citation></ref><ref id="b20-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>MF</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Forkert</surname><given-names>L</given-names></name></person-group><year>2002</year><article-title>Responses of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation</article-title><source>Chest</source><volume>121</volume><fpage>1042</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11948031</pub-id></citation></ref><ref id="b21-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name></person-group><year>2000</year><article-title>Assessment of bronchodilator efficacy in symptomatic COPD. Is spirometry useful?</article-title><source>Chest</source><volume>117</volume><fpage>42</fpage><lpage>7</lpage></citation></ref><ref id="b22-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Buist</surname><given-names>AS</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><etal/></person-group><year>2001</year><article-title>Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease [GOLD] Workshop summary</article-title><source>Am J Resp Crit Care Med</source><volume>163</volume><fpage>1256</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">11316667</pub-id></citation></ref><ref id="b23-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pellegrino</surname><given-names>R</given-names></name><name><surname>Rodarte</surname><given-names>JR</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name></person-group><year>1998</year><article-title>Assessing the reversibility of airway obstruction</article-title><source>Chest</source><volume>114</volume><fpage>1607</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">9872196</pub-id></citation></ref><ref id="b24-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>Tammeling</surname><given-names>GJ</given-names></name><name><surname>Cotes</surname><given-names>JE</given-names></name><etal/></person-group><year>1993</year><article-title>Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society</article-title><source>Eur Respir J</source><volume>6</volume><fpage>5</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">8381090</pub-id></citation></ref><ref id="b25-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quedrelli</surname><given-names>SA</given-names></name><name><surname>Roncoroni</surname><given-names>AJ</given-names></name><name><surname>Montiel</surname><given-names>GC</given-names></name></person-group><year>1999a</year><article-title>Assessment of respiratory function: influence of spirometry reference values and normality criteria selection</article-title><source>Respir Med</source><volume>93</volume><fpage>523</fpage><lpage>35</lpage></citation></ref><ref id="b26-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quedrelli</surname><given-names>SA</given-names></name><name><surname>Roncoroni</surname><given-names>AJ</given-names></name><name><surname>Montiel</surname><given-names>GC</given-names></name></person-group><year>1999b</year><article-title>Evaluation of bronchodilator response in patients with airway obstruction</article-title><source>Respir Med</source><volume>93</volume><fpage>630</fpage><lpage>6</lpage></citation></ref><ref id="b27-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sterk</surname><given-names>PJ</given-names></name></person-group><year>2004</year><article-title>Let&#x02019;s not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV<sub>1</sub></article-title><source>Eur Respir J</source><volume>23</volume><fpage>497</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15083741</pub-id></citation></ref><ref id="b28-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tweeddale</surname><given-names>PM</given-names></name><name><surname>Alexander</surname><given-names>F</given-names></name><name><surname>McHardy</surname><given-names>GJR</given-names></name></person-group><year>1987</year><article-title>Short term variability and bronchodilator responsiveness in patients with obstructive in FEV<sub>1</sub> ventilatory defects</article-title><source>Thorax</source><volume>42</volume><fpage>487</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">3438892</pub-id></citation></ref><ref id="b29-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viegi</surname><given-names>G</given-names></name><name><surname>Pedreschi</surname><given-names>M</given-names></name><name><surname>Pistelli</surname><given-names>F</given-names></name><etal/></person-group><year>2000</year><article-title>Prevalence of airways obstruction in a general population. European Respiratory Society vs American Thoracic Society definition</article-title><source>Chest</source><volume>117</volume><fpage>339</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">10669672</pub-id></citation></ref><ref id="b30-copd-3-693"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>DC</given-names></name><name><surname>Burge</surname><given-names>PS</given-names></name></person-group><year>1991</year><article-title>Measures of reversibility in response to bronchodilators in chronic airflow obstruction: relation to airway caliber</article-title><source>Thorax</source><volume>46</volume><fpage>43</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1831301</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="f1-copd-3-693" position="float"><label>Figure 1</label><caption><p>Post bronchodilator FEV<sub>1</sub> % predicted (<inline-graphic xlink:href="copd-3-693ig1.jpg"/>) and FEV<sub>1</sub>/FVC ratio (<inline-graphic xlink:href="copd-3-693ig2.jpg"/>) with horizontal bars indicating confidence limits for means at 95% confidence interval.</p></caption><graphic xlink:href="copd-3-693f1"/></fig><fig id="f2-copd-3-693" position="float"><label>Figure 2</label><caption><p>Bronchodilator response expressed as an increased percentage from initial FEV<sub>1</sub> (<inline-graphic xlink:href="copd-3-693ig1.jpg"/>) and as an increase percentage from the predicted FEV<sub>1</sub> (<inline-graphic xlink:href="copd-3-693ig2.jpg"/>). Horizontal bars indicate confidence limits for means at 95% confidence interval.</p></caption><graphic xlink:href="copd-3-693f2"/></fig><table-wrap id="t1-copd-3-693" position="float"><label>Table 1</label><caption><p>Baseline pre-bronchodilator subject characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">COPD</th><th align="left" rowspan="1" colspan="1">Asthma</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Subjects <italic>n</italic></td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">F:M</td><td align="left" rowspan="1" colspan="1">13:9</td><td align="left" rowspan="1" colspan="1">11:10</td></tr><tr><td align="left" rowspan="1" colspan="1">Age yrs</td><td align="left" rowspan="1" colspan="1">52.2 (1.15)</td><td align="left" rowspan="1" colspan="1">50.1 (1.44)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pack years</td><td align="left" rowspan="1" colspan="1">43.8 (2.9)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td colspan="3" align="left" rowspan="1">Medication</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Short acting &#x003b2;<sub>2</sub>-agonist</td><td align="left" rowspan="1" colspan="1">22 (100%)</td><td align="left" rowspan="1" colspan="1">21 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Short acting anticholinergic</td><td align="left" rowspan="1" colspan="1">15 (68%)</td><td align="left" rowspan="1" colspan="1">6 (29%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Long acting &#x003b2;<sub>2</sub>-agonist</td><td align="left" rowspan="1" colspan="1">5 (23%)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Long acting anticholinergic</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Inhaled corticosteroid</td><td align="left" rowspan="1" colspan="1">9 (41%)</td><td align="left" rowspan="1" colspan="1">21 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Theophylline</td><td align="left" rowspan="1" colspan="1">8 (36%)</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Height cm</td><td align="left" rowspan="1" colspan="1">1.64 (0.18)</td><td align="left" rowspan="1" colspan="1">1.68 (0.02)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight kg</td><td align="left" rowspan="1" colspan="1">69.23 (3.56)</td><td align="left" rowspan="1" colspan="1">79.61 (2.78)<xref ref-type="table-fn" rid="tfn3-copd-3-693">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">BMI kgm<sup>2</sup></td><td align="left" rowspan="1" colspan="1">25.6 (1.25)</td><td align="left" rowspan="1" colspan="1">28.1 (0.94)</td></tr><tr><td colspan="3" align="left" rowspan="1">Spirometry</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub> L</td><td align="left" rowspan="1" colspan="1">1.57 (0.10)</td><td align="left" rowspan="1" colspan="1">1.80 (0.10)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;%pred</td><td align="left" rowspan="1" colspan="1">55.74 (1.63)</td><td align="left" rowspan="1" colspan="1">59.29 (1.82)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FVC L</td><td align="left" rowspan="1" colspan="1">2.82 (0.16)</td><td align="left" rowspan="1" colspan="1">3.17 (0.18)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;%pred</td><td align="left" rowspan="1" colspan="1">83.5 (1.98)</td><td align="left" rowspan="1" colspan="1">86.5 (2.74)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEF<sub>50</sub> L</td><td align="left" rowspan="1" colspan="1">0.90 (0.07)</td><td align="left" rowspan="1" colspan="1">1.05 (0.06)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;%pred</td><td align="left" rowspan="1" colspan="1">21.79 (1.52)</td><td align="left" rowspan="1" colspan="1">24.45 (1.24)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>/FVC%</td><td align="left" rowspan="1" colspan="1">55.74 (0.99)</td><td align="left" rowspan="1" colspan="1">57.65 (1.16)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-copd-3-693"><p><bold>Abbreviations:</bold> COPD, chronic obstructive pulmonary disease; F, female; M, male; BMI, body mass index; FEV<sub>1</sub>, forced expiratory volume in one second; FVC, forced vital capacity; FEF<sub>50,</sub> foced expiratory flow at 50% of FVC; %pred, percentage of predicted.</p></fn><fn id="tfn2-copd-3-693"><p><bold>Notes:</bold> Data are presented as mean &#x000b1; SEM. Spirometric comparisons between groups were made only between % pred normal values.</p></fn><fn id="tfn3-copd-3-693"><label>*</label><p><italic>p</italic> &#x0003c; 0.05, significant difference between groups.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-copd-3-693" position="float"><label>Table 2</label><caption><p>Responses to 400 &#x003bc;g salbutamol metered dose inhaler</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">COPD</th><th align="left" rowspan="1" colspan="1">Asthma</th></tr></thead><tbody><tr><td colspan="3" align="left" rowspan="1"><bold>FEV</bold><sub>1</sub></td></tr><tr><td align="left" rowspan="1" colspan="1">%pred (post bd)</td><td align="left" rowspan="1" colspan="1">63 (1.5)</td><td align="left" rowspan="1" colspan="1">75 (2.1)<xref ref-type="table-fn" rid="tfn6-copd-3-693">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">%&#x00394;init</td><td align="left" rowspan="1" colspan="1">13 (3)</td><td align="left" rowspan="1" colspan="1">27 (3)<xref ref-type="table-fn" rid="tfn6-copd-3-693">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">%&#x00394;pred</td><td align="left" rowspan="1" colspan="1">7 (2)</td><td align="left" rowspan="1" colspan="1">15 (2)<xref ref-type="table-fn" rid="tfn6-copd-3-693">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">abs&#x00394;L</td><td align="left" rowspan="1" colspan="1">0.185 (0.04)</td><td align="left" rowspan="1" colspan="1">0.445 (0.03)<xref ref-type="table-fn" rid="tfn6-copd-3-693">***</xref></td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>FVC</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">%pred (post bd)</td><td align="left" rowspan="1" colspan="1">90 (3)</td><td align="left" rowspan="1" colspan="1">97 (3) ns</td></tr><tr><td align="left" rowspan="1" colspan="1">%&#x00394;init</td><td align="left" rowspan="1" colspan="1">8 (3)</td><td align="left" rowspan="1" colspan="1">13 (2) ns</td></tr><tr><td align="left" rowspan="1" colspan="1">%&#x00394;pred</td><td align="left" rowspan="1" colspan="1">6 (2)</td><td align="left" rowspan="1" colspan="1">11 (2) ns</td></tr><tr><td align="left" rowspan="1" colspan="1">abs&#x00394;L</td><td align="left" rowspan="1" colspan="1">0.193 (0.07)</td><td align="left" rowspan="1" colspan="1">0.375 (0.05)<xref ref-type="table-fn" rid="tfn6-copd-3-693">*</xref></td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>FEF</bold><sub>50</sub></td></tr><tr><td align="left" rowspan="1" colspan="1">%pred (post bd)</td><td align="left" rowspan="1" colspan="1">25 (2)</td><td align="left" rowspan="1" colspan="1">36 (2)<xref ref-type="table-fn" rid="tfn6-copd-3-693">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">%&#x00394;init</td><td align="left" rowspan="1" colspan="1">18 (6)</td><td align="left" rowspan="1" colspan="1">52 (6)<xref ref-type="table-fn" rid="tfn6-copd-3-693">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">%&#x00394;pred</td><td align="left" rowspan="1" colspan="1">4 (1)</td><td align="left" rowspan="1" colspan="1">12 (1)<xref ref-type="table-fn" rid="tfn6-copd-3-693">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">abs&#x00394;L</td><td align="left" rowspan="1" colspan="1">0.151 (0.05)</td><td align="left" rowspan="1" colspan="1">0.492 (0.05)<xref ref-type="table-fn" rid="tfn6-copd-3-693">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FEV</bold><bold>1</bold>/<bold>FVC</bold>(post bd)</td><td align="left" rowspan="1" colspan="1">58 (2)</td><td align="left" rowspan="1" colspan="1">64 (1)<xref ref-type="table-fn" rid="tfn6-copd-3-693">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn4-copd-3-693"><p><bold>Abbreviations:</bold> FEV<sub>1</sub>, forced expiratory volume in one second; FVC, forced vital capacity; FEF<sub>50</sub>, forced expiratory flow at 50% of FVC; % pred, percentage of predicted; %&#x00394;init, percentage change from initial; %&#x00394;pred, percentage change from predicted; abs&#x00394;, absolute change.</p></fn><fn id="tfn5-copd-3-693"><p><bold>Note:</bold> Data are presented as mean &#x000b1; SEM</p></fn><fn id="tfn6-copd-3-693"><label>*</label><p><italic>p</italic> &#x0003c; 0.01, <italic>p</italic> &#x0003c; 0.001, <italic>p</italic> &#x0003c; 0.0001, significant difference in COPD versus asthma groups.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-copd-3-693" position="float"><label>Table 3</label><caption><p>Sensitivity, specificity, predictive values and accuracy of each lung function criteria to diagnose COPD based on the bronchodilator response</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Lung function criteria</th><th align="left" rowspan="1" colspan="1">Cutoff level</th><th align="left" rowspan="1" colspan="1">Sensitivity %</th><th align="left" rowspan="1" colspan="1">Specificity %</th><th align="left" rowspan="1" colspan="1">Positive predictive value, %</th><th align="left" rowspan="1" colspan="1">Negative predictive value, %</th><th align="left" rowspan="1" colspan="1">Accuracy %</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Post bronchodilator</td><td align="left" rowspan="1" colspan="1">&#x0003c;70% and 80%</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">70</td></tr><tr><td colspan="7" align="left" rowspan="1">FEV<sub>1</sub>/FVC % and FEV<sub>1</sub> %pred</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV<sub>1</sub>%&#x00394;init and&#x00394;abs</td><td align="left" rowspan="1" colspan="1">&#x0003c;12% and 200 mL</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">67</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV<sub>1</sub>&#x00394; % pred</td><td align="left" rowspan="1" colspan="1">&#x0003c;9%</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">67</td></tr></tbody></table><table-wrap-foot><fn id="tfn7-copd-3-693"><p><bold>Abbreviations:</bold> FEV<sub>1</sub>, forced expiratory volume in one second; FVC, forced vital capacity; %&#x00394;init, percentage change from initial; abs&#x00394;, absolute change; %&#x00394;pred, percentage change from predicted; %&#x00394;pred, percentage of predicted.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>